AEON Biopharma financials
$0.2590−0.99%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$5.9M | -$5.9M | -$5.5M | -$2.5M | -$4.3M | -$462.0K | -$2.3M | -$4.0M | $153.5M | -$74.2M | -$376.3M | -$286.3M |
| Net income | -$1.2M | -$11.8M | -$37.1M | -$4.5M | -$6.6M | $9.1M | $2.1M | -$6.2M | $164.1M | -$118.0M | -$346.6M | -$325.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.02 | $-0.29 | $-2.86 | $-0.39 | $-0.60 | $2.28 | $2.99 | $-11.24 | $304.00 | $-227.87 | — | $-630.72 |
| EBITDA | -$5.9M | -$5.9M | -$5.5M | -$2.5M | -$4.3M | -$443.0K | -$2.3M | -$4.0M | $153.5M | -$74.1M | -$376.3M | -$362.3M |
| Operating cash flow | -$3.7M | -$2.6M | -$4.7M | -$2.6M | -$2.1M | -$7.9M | -$621.0K | -$3.0M | -$8.1M | -$8.6M | — | — |
| Free cash flow | -$3.7M | -$2.6M | -$4.7M | -$2.6M | -$2.1M | -$7.9M | -$621.0K | -$3.0M | -$8.1M | -$8.6M | — | — |
| Diluted shares | 50.5M | 40.6M | 13.0M | 11.6M | 11.1M | 4.0M | 0.7M | 0.5M | 0.5M | 0.5M | — | 0.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.4M | $6.2M | $3.0M | $5.9M | $8.4M | $10.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $2.7M | $2.7M | $36.0M | $18.6M | $16.8M | $16.3M |
| Total assets | $5.9M | $8.6M | $5.6M | $8.7M | $11.7M | $13.8M |
| Total liabilities | $21.3M | $25.4M | $60.6M | $28.6M | $27.5M | $25.1M |
| Shareholders' equity | -$15.4M | -$16.8M | -$55.0M | -$19.9M | -$15.9M | -$11.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology